



© Copyright 2024 Oregon State University. All Rights Reserved

Drug Use Research & Management Program
Oregon State University, 500 Summer Street NE, E35
Salem, Oregon 97301-1079
Phone 503-947-5220 | Fax 503-947-2596



Drug Class Literature Scan: Topical Steroids

Date of Review: August 2026

Literature Search: 1/1/2017 – 6/10/2026

Date of Last Review: September 2017 (topical steroids)

December 2025 (topical products for inflammatory skin disease)

Current Status of PDL Class:

See **Appendix 1**.

Plain Language Summary:

- This review looked for new evidence on the safety and effectiveness of steroid creams, ointments, and lotions applied to the skin (topical steroids).
- Topical steroids are used to manage symptoms associated with skin conditions such as eczema (also called atopic dermatitis), insect bites, allergic dermatitis from contact with poison ivy, psoriasis, and vitiligo. When applied to the skin, steroids decrease redness, itch, swelling, irritation, and rash.
- Steroids vary in potency from very strong (clobetasol, betamethasone, halobetasol) to mild (hydrocortisone, triamcinolone). It is best to start with low potency corticosteroids to avoid side effects such as thinning skin or acne, especially when treating areas of thin skin such as the face or eyelids. Thinning of skin can make it easier to break, bruise, or stretch. Higher potency corticosteroids are recommended for more severe skin conditions. All topical steroids should be used for a short time to limit side effects.
- No new evidence was identified that suggest changes to the preferred drug list (PDL) under the Oregon Health Plan (OHP) are recommended.

Conclusions:

- Since the last review of topical agents for inflammatory skin conditions, one new high-quality clinical guideline was identified; one new topical steroid formulation was approved by the Food and Drug Administration (FDA); and one topical steroid received an expanded indication in pediatric patients.
- The American Academy of Dermatology (AAD) updated their guideline to provide evidence-based recommendations for topical therapies phototherapy, and systemic therapies for children under 18 years of age with atopic dermatitis (AD) of any severity.¹ For pediatric patients up to age 18 with AD, topical corticosteroids are strongly recommended based upon moderate-quality evidence.¹ No specific agent is recommended over another.
- In November 2017, FDA approved IMPOYZ (clobetasol propionate 0.025% cream) for treatment of moderate to severe plaque psoriasis in patients 18 years of age and older.²
- In August 2020, FDA expanded the indication for ULTRAVATE (halobetasol propionate lotion) for the treatment of plaque psoriasis in patients 12 years of age and older.³ The previously approved indicated was for adults only.³
- Recent FDA safety labeling changes are presented in **Table 1**.

Recommendations:

- Current evidence does not warrant changes to the preferred drug list (PDL) (**Appendix 1**).
- After reviewing drug costs in the executive session, the following recommendations were accepted:
 - Make all hydrocortisone rectal products, hydrocortisone-aloe cream, clobetasol shampoo, emollient cream, gel and foam, hydrocortisone lotion, fluticasone cream and ointment, desonide lotion, betamethasone valerate lotion, betamethasone ointment and foam, betamethasone pg ointment, triamcinolone lotion, halobetasol ointment and cream, fluocinolone solution, gel, oil, and ointment, fluocinolone shower cap oil, fluocinonide ointment and gel, and mometasone cream, ointment and solution preferred.
 - Make hydrocortisone gel, fluocinonide-dimethicone kit, and clobetasol 0.025% cream nonpreferred.

Summary of Prior Reviews and Current Policy

- The Pharmacy and Therapeutics (P&T) Committee reviewed topical products for inflammatory skin diseases at the December 2025 meeting. Recently published evidence showed the most effective medicines to treat atopic dermatitis (AD) included topical corticosteroids among other classes of topical therapies (i.e., calcineurin inhibitors, Janus kinase inhibitors, and phosphodiesterase-4 inhibitors).⁴ The 2023 American Academy of Dermatology (AAD) guidance for management of AD with topical therapies in adults strongly recommends topical steroids for management of mild to severe AD.⁵ According to the 2021 American Academy of Dermatology/National Psoriasis Foundation (AAD/NPF) guidance, first-line topical agents to treat mild-to-moderate plaque psoriasis (PsO) includes topical steroids.⁶ The 2021 British Association of Dermatologists (BAD) guidance recommends high potency or very high potency topical steroids as first-line treatment for vitiligo.⁷ However, use of topical steroids to treat vitiligo is off-label.⁸
- The PDL status for topical steroids is provided in **Appendix 1**. Preferred topical steroids include lotion, cream, and ointment formulations of betamethasone, clobetasol, desonide, fluocinolone, hydrocortisone, and triamcinolone. All other topical steroids and formulations are subject to standard nonpreferred prior authorization (PA) criteria. The comparative potency of topical corticosteroids is presented in **Appendix 2**.

Methods:

A Medline literature search for new systematic reviews and randomized controlled trials (RCTs) assessing clinically relevant outcomes to active controls, or placebo if needed, was conducted. The Medline search strategy used for this literature scan is available in **Appendix 4**, which includes dates, search terms and limits used. The OHSU Drug Effectiveness Review Project, Agency for Healthcare Research and Quality (AHRQ), National Institute for Health and Clinical Excellence (NICE), Department of Veterans Affairs, the Scottish Intercollegiate Guidelines Network (SIGN), and the Canada's Drug Agency (CDA-AMA) resources were manually searched for high quality and relevant systematic reviews. When necessary, systematic reviews are critically appraised for quality using the AMSTAR tool and clinical practice guidelines using the AGREE tool. The FDA website was searched for new drug approvals, indications, and pertinent safety alerts.

The primary focus of the evidence is on high-quality systematic reviews and evidence-based guidelines. Randomized controlled trials will be emphasized if evidence is lacking or insufficient from those preferred sources.

New Systematic Reviews:

No new high-quality systematic reviews have been published since the December 2025 P&T Committee review of topical inflammatory agents.

New Guidelines:

American Academy of Dermatology Guidance for Management of Atopic Dermatitis In Pediatric Patients (2026)

The AAD updated guidelines to provide evidence-based recommendations for topical therapies phototherapy, and systemic therapies for children under 18 years of age with AD of any severity.¹ Recommendations that specifically address use of topical corticosteroids for AD include:

- For pediatric patients up to age 18 with AD, topical corticosteroids are recommended (Strong Recommendation; Moderate-Quality Evidence).¹
- For pediatric patients up to age 18 with AD, intermittent use of low to medium potency topical corticosteroids as maintenance therapy is recommended (up to 3 times per week) (Strong Recommendation; Moderate-Quality Evidence).¹

One identified guideline was excluded due to poor quality.⁹

New Formulations and Indications:

11/2017: FDA approved IMPOYZ, a topical formulation of clobetasol propionate 0.025% cream, indicated for treatment of moderate to severe plaque psoriasis in patients 18 years of age and older.² The safety and efficacy of clobetasol 0.025% cream was evaluated in 2 double-blind, vehicle-controlled RCTs which enrolled a total of 532 participants aged 18 years and older with moderate to severe plaque psoriasis.² Participants were treated twice daily with clobetasol 0.025% cream or vehicle cream for 14 days.² The primary endpoint was the proportion of subjects who achieved treatment success at 15 day, where treatment success was defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-grade reduction from baseline.² In both RCTs, more participants achieved statistically significant treatment success at Day 15 with clobetasol compared to vehicle (30% vs. 9%; 95% confidence interval not reported; $p < 0.001$).²

8/2020: ULTRAVATE (halobetasol propionate) lotion received an expanded indication for the treatment of plaque psoriasis in patients 12 years of age and older.³ It had been previously approved for treatment of plaque psoriasis in patients aged 18 years and older.³ The safety and of halobetasol lotion was evaluated in one open-label study in 16 adolescents with moderate to severe plaque psoriasis; evidence for efficacy was previously supported in trials conducted in adults.³ Hypothalamic-pituitary adrenal (HPA) axis function (ACTH stimulation test) was evaluated in a subset of 14 patients.³ After 2 weeks of treatment, 1 of 14 patients (7%) experienced laboratory evidence of adrenal suppression (i.e., cortisol serum level of ≤ 18 mcg/dL) that recovered upon retest. No other adverse reactions were reported in the study.³

New FDA Safety Alerts:

Table 1. Description of New FDA Safety Alerts¹⁰

Generic Name	Brand Name	Month / Year of Change	Location of Change (Boxed Warning, Warnings, CI)	Addition or Change and Mitigation Principles (if applicable)
Betamethasone Clobetasol Mometasone	DIPROLENE, LOTRISONE OLUX ELOCON	3/2018	Warnings and Precautions	Use of topical corticosteroids may increase the risk of posterior subcapsular cataracts and glaucoma. Cataracts and glaucoma have been reported postmarketing with the use of topical corticosteroid products.

				Avoid contact of topical corticosteroids Ointment with eyes. Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation.
Desoximetasone	TOPICORT	10/2021	Warnings and Precautions	Pediatric patients may be more susceptible to systemic toxicity from use of topical corticosteroids. Use in patients under 18 years of age is not recommended due to numerically high rates of HPA axis suppression (the safety and effectiveness of Topicort Topical Spray have not been established in pediatric patients).

References:

1. Davis DMR, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in pediatric patients. *Journal of the American Academy of Dermatology*. doi:10.1016/j.jaad.2026.02.113
2. IMPOYZ (clobetasol propionate) topical 0.025% cream. Prescribing Information. San Antonio, TX; Promius Pharma LLC. 11/2017.
3. ULTRAVATE (halobetasol propionate) 0.05% topical lotion. Prescribing Information. Ferndale, MI; Ferndale Laboratories, Inc. 8/2020.
4. Lax SJ, Van Vogt E, Candy B, et al. Topical Anti-Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta-Analysis. *Clin Exp Allergy*. Dec 2024;54(12):960-972. doi:10.1111/cea.14556
5. Davis DMR, Frazer-Green L, Alikhan A, et al. Focused update: Guidelines of care for the management of atopic dermatitis in adults. *Journal of the American Academy of Dermatology*. 2025;93(3):745.e1-745.e7. doi:10.1016/j.jaad.2025.05.1386
6. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol*. Feb 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087
7. Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. *Br J Dermatol*. Jan 2022;186(1):18-29. doi:10.1111/bjd.20596
8. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at <http://www.micromedexsolutions.com>. Accessed 12/12/2025.
9. Renert-Yuval Y, Ezzedine K, Grimes P, et al. Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients. *JAMA Dermatol*. Apr 1 2024;160(4):453-461. doi:10.1001/jamadermatol.2024.0021
10. Food and Drug Administration. Drug Safety Labeling Changes (SLC). <https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/>. Accessed May 6, 2026.

Appendix 1: Current Preferred Drug List

<u>Generic</u>	<u>Brand</u>	<u>Form</u>	<u>PDL</u>
alclometasone dipropionate	ALCLOMETASONE DIPROPIONATE	CREAM (G)	Y
alclometasone dipropionate	ALCLOMETASONE DIPROPIONATE	OINT. (G)	Y
betamethasone dipropionate	BETAMETHASONE DIPROPIONATE	CREAM (G)	Y
betamethasone dipropionate	ALPHATREX	LOTION	Y
betamethasone dipropionate	BETAMETHASONE DIPROPIONATE	LOTION	Y

betamethasone dipropionate	ALPHATREX	OINT. (G)	Y
betamethasone dipropionate	BETAMETHASONE DIPROPIONATE	OINT. (G)	Y
betamethasone valerate	BETAMETHASONE VALERATE	CREAM (G)	Y
betamethasone valerate	BETATREX	CREAM (G)	Y
betamethasone valerate	BETAMETHASONE VALERATE	OINT. (G)	Y
betamethasone valerate	BETATREX	OINT. (G)	Y
betamethasone/propylene glyc	BETAMETHASONE DIPROP AUGMENTED	CREAM (G)	Y
clobetasol propionate	CLOBETASOL PROPIONATE	CREAM (G)	Y
clobetasol propionate	CLOBETASOL PROPIONATE	OINT. (G)	Y
clobetasol propionate	CLOBETASOL PROPIONATE	SOLUTION	Y
desonide	DESONIDE	CREAM (G)	Y
desonide	DESOWEN	CREAM (G)	Y
desonide	TRIDESILON	CREAM (G)	Y
desonide	DESONIDE	OINT. (G)	Y
desonide	TRIDESILON	OINT. (G)	Y
desoximetasone	DESOXIMETASONE	CREAM (G)	Y
fluocinolone acetonide	FLUOCINOLONE ACETONIDE	CREAM (G)	Y
fluocinolone acetonide	SYNALAR	CREAM (G)	Y
fluocinolone acetonide	FLUOCINOLONE ACETONIDE	SOLUTION	Y
fluocinolone acetonide	SYNALAR	SOLUTION	Y
fluocinonide	FLUOCINONIDE	CREAM (G)	Y
fluocinonide	FLUOCINONIDE	SOLUTION	Y
fluocinonide/emollient base	FLUOCINONIDE-E	CREAM (G)	Y
hydrocortisone	ANTI-ITCH	CREAM (G)	Y
hydrocortisone	HYDROCORTISONE	CREAM (G)	Y
hydrocortisone	HYCORT	OINT. (G)	Y
hydrocortisone	HYDROCORTISONE	OINT. (G)	Y
hydrocortisone	ITCH RELIEF	OINT. (G)	Y
hydrocortisone acetate	HYDROCORTISONE ACETATE	CREAM (G)	Y
hydrocortisone butyrate	HYDROCORTISONE BUTYRATE	SOLUTION	Y
triamcinolone acetonide	TRIAMCINOLONE ACETONIDE	CREAM (G)	Y
triamcinolone acetonide	TRIAMCINOLONE ACETONIDE	OINT. (G)	Y
amcinonide	AMCINONIDE	CREAM (G)	N
betamethasone dipropionate	DIPROSONE	AEROSOL	N
betamethasone dipropionate	BETAMETHASONE DIPROP AUGMENTED	GEL (GRAM)	N
betamethasone valerate	BETAMETHASONE VALERATE	FOAM	N
betamethasone valerate	BETAMETHASONE VALERATE	LOTION	N
betamethasone/propylene glyc	BETAMETHASONE DIPROP AUGMENTED	LOTION	N
betamethasone/propylene glyc	BETAMETHASONE DIPROP AUGMENTED	OINT. (G)	N
clobetasol propionate	CLOBETASOL PROPIONATE	FOAM	N

clobetasol propionate	CLOBETASOL PROPIONATE	GEL (GRAM)	N
clobetasol propionate	CLOBETASOL PROPIONATE	LOTION	N
clobetasol propionate	CLOBETASOL PROPIONATE	SHAMPOO	N
clobetasol propionate	CLOBEX	SHAMPOO	N
clobetasol propionate	CLODAN	SHAMPOO	N
clobetasol propionate	CLOBETASOL PROPIONATE	SPRAY	N
clobetasol propionate	CLOBEX	SPRAY	N
clobetasol propionate/emoll	CLOBETASOL EMOLLIENT	CREAM (G)	N
clobetasol propionate/emoll	CLOBETASOL EMOLLIENT	FOAM	N
clobetasol propionate/emoll	CLOBETASOL EMULSION	FOAM	N
clobetasol propionate/emoll	TOVET EMOLLIENT	FOAM	N
clobetasol/emollient no.65	TOVET KIT	COMBO. PKG	N
clobetasol/skin cleanser no.28	CLODAN	KT SHM CLN	N
clocortolone pivalate	CLOCORTOLONE PIVALATE	CREAM (G)	N
desonide	DESONIDE	LOTION	N
desoximetasone	DESOXIMETASONE	GEL (GRAM)	N
desoximetasone	DESOXIMETASONE	OINT. (G)	N
desoximetasone	DESOXIMETASONE	SPRAY	N
diflorasone diacetate	DIFLORASONE DIACETATE	CREAM (G)	N
diflorasone diacetate	DIFLORASONE DIACETATE	OINT. (G)	N
fluocinolone acetonide	DERMA-SMOOTHIE-FS	OIL	N
fluocinolone acetonide	FLUOCINOLONE ACETONIDE	OIL	N
fluocinolone acetonide	FLUOCINOLONE ACETONIDE	OINT. (G)	N
fluocinolone acetonide	SYNALAR	OINT. (G)	N
fluocinolone acetonide	CAPEX SHAMPOO	SHAMPOO	N
fluocinolone/emol comb no.65	SYNALAR	CMB ONT CR	N
fluocinolone/emol comb no.65	SYNALAR	CREAM (G)	N
fluocinolone/shower cap	DERMA-SMOOTHIE-FS	OIL	N
fluocinolone/shower cap	FLUOCINOLONE ACETONIDE	OIL	N
fluocinolone/skin clnsr28	SYNALAR TS	KIT	N
fluocinonide	FLUOCINONIDE	GEL (GRAM)	N
fluocinonide	FLUOCINONIDE	OINT. (G)	N
flurandrenolide	FLURANDRENOLIDE	LOTION	N
fluticasone propionate	FLUTICASONE PROPIONATE	CREAM (G)	N
fluticasone propionate	BESER	LOTION	N
fluticasone propionate	FLUTICASONE PROPIONATE	LOTION	N
fluticasone propionate	FLUTICASONE PROPIONATE	OINT. (G)	N
fluticasone/emollient no.65	BESER KIT	KT LOTN CE	N
halcinonide	HALCINONIDE	CREAM (G)	N
halcinonide	HALOG	CREAM (G)	N

halcinonide	HALCINONIDE	SOLUTION	N
halcinonide	HALOG	SOLUTION	N
halobetasol propionate	HALOBETASOL PROPIONATE	CREAM (G)	N
halobetasol propionate	HALOBETASOL PROPIONATE	FOAM	N
halobetasol propionate	LEXETTE	FOAM	N
halobetasol propionate	HALOBETASOL PROPIONATE	LOTION	N
halobetasol propionate	ULTRAVATE	LOTION	N
halobetasol propionate	HALOBETASOL PROPIONATE	OINT. (G)	N
hydrocortisone	HYDROCORTISONE	CREAM PACK	N
hydrocortisone	CETACORT	LOTION	N
hydrocortisone	HYDROCORTISONE	LOTION	N
hydrocortisone	SCALP CORT	LOTION	N
hydrocortisone	HYDROCORTISONE	SOLUTION	N
hydrocortisone	SCALP	SOLUTION	N
hydrocortisone	TEXACORT	SOLUTION	N
hydrocortisone	HYDROCORTISONE	SPRAY	N
hydrocortisone acet/aloë vera	HYDROCORTISONE ACETATE W/ALOE	CREAM (G)	N
hydrocortisone acet/aloë vera	HYDROCORTISONE W/ALOE	CREAM (G)	N
hydrocortisone acet/aloë vera	HYDROCORTISONE ACETATE W/ALOE	OINT. (G)	N
hydrocortisone acet/aloë vera	HYDROCORTISONE W/ALOE	OINT. (G)	N
hydrocortisone acet/aloë vera	HYDROCORTISONE W/ALOE	PACKET	N
hydrocortisone acetate	HYDROCORTISONE	OINT. (G)	N
hydrocortisone acetate	HYDROCORTISONE ACETATE	OINT. (G)	N
hydrocortisone butyrate	HYDROCORTISONE BUTYRATE	CREAM (G)	N
hydrocortisone butyrate	HYDROCORTISONE BUTYRATE	LOTION	N
hydrocortisone butyrate	HYDROCORTISONE BUTYRATE	OINT. (G)	N
hydrocortisone probutate	PANDEL	CREAM (G)	N
hydrocortisone valerate	HYDROCORTISONE VALERATE	CREAM (G)	N
hydrocortisone valerate	HYDROCORTISONE VALERATE	OINT. (G)	N
hydrocortisone/aloë vera	HYDROCORTISONE W/ALOE	CREAM (G)	N
hydrocortisone/aloë vera	HYDROCORTISONE-ALOE	CREAM (G)	N
hydrocortisone/aloë vera	ITCH RELIEF WITH ALOE	CREAM (G)	N
hydrocortisone/aloë vera	HYDROCORTISONE W/ALOE	OINT. (G)	N
mometasone furoate	MOMETASONE FUROATE	CREAM (G)	N
mometasone furoate	MOMETASONE FUROATE	OINT. (G)	N
mometasone furoate	MOMETASONE FUROATE	SOLUTION	N
neomycin sulfate/fluocinolone	NEO-SYNALAR	CREAM (G)	N
neomycin/fluocinolone/emoll 65	NEO-SYNALAR	CREAM (G)	N
triamcinolone acetonide	TRIAMCINOLONE ACETONIDE	AEROSOL	N
triamcinolone acetonide	KENALOG	LOTION	N

triamcinolone acetonide	TRIAMCINOLONE ACETONIDE	LOTION	N
hydrocortisone	HYDROCORTISONE	CRM/PE APP	
hydrocortisone	PROCTO-MED HC	CRM/PE APP	
hydrocortisone	PROCTOSOL-HC	CRM/PE APP	
hydrocortisone	PROCTOZONE-HC	CRM/PE APP	
hydrocortisone	HYDRAVEX	GEL (GRAM)	
hydrocortisone	HYDROCORTISONE	GEL (GRAM)	
hydrocortisone	HYDROXYM	GEL (GRAM)	
hydrocortisone acetate	MICORT-HC	CRM/PE APP	
neomycin sulfate/hydrocort	NEOMYCIN W/HYDROCORTISONE	OINT. (G)	

Appendix 2: Comparative Potency of Topical Corticosteroids

Table 2. Potency Of Topical Corticosteroid Preparations Using United States Classification.⁶

Potency Group	Corticosteroid	Strength	Formulation
Lowest Potency (Group 7)	Hydrocortisone Base and Hydrocortisone Acetate	0.5%, 1.0%, 2.0%	cream, ointment, gel, lotion, solution
Low Potency (Group 6)	Alcometasone dipropionate	0.05%	cream, ointment
	Betamethasone valerate	0.05%	lotion
	Desonide	0.05%	cream
	Fluocinolone acetonide	0.01%	cream, oil, shampoo, solution
	Triamcinolone acetonide	0.1%	cream
Medium-Low Potency (Group 5)	Betamethasone dipropionate	0.05%	lotion
	Betamethasone valerate	0.1%	cream
	Betamethasone valerate	0.01%	cream, lotion
	Desonide	0.05%	lotion, ointment
	Fluocinolone acetonide	0.025%	cream
	Flurandrenolide	0.05%	cream
	Fluticasone propionate	0.05%	cream
	Hydrocortisone butyrate	0.1%	cream
	Hydrocortisone valerate	0.2%	cream
	Prednicarbate	0.1%	cream
	Triamcinolone acetonide	0.1%	lotion
Medium Potency (Group 4)	Betamethasone valerate	0.12%	foam
	Desoximetasone	0.05%	cream
	Fluocinolone acetonide	0.025%	ointment
	Fluocinolone acetonide	0.2%	cream
	Flurandrenolide	0.05%	ointment
	Halcinonide	0.025%	cream
	Hydrocortisone probutate	0.1%	cream

	Hydrocortisone valerate	0.2%	cream
	Mometasone furoate	0.1%	cream, lotion, solution
	Prednicarbate	0.1%	ointment
Medium-High Potency (Group 3)	Amcinonide	0.1%	cream, lotion
	Betamethasone valerate	0.1%	ointment
	Diflorasone diacetate	0.05%	cream
	Fluocinonide	0.05%	cream
	Fluticasone propionate	0.005%	ointment
	Halcinonide	0.1%	ointment, solution
	Triamcinolone acetonide	0.5%	cream
	Triamcinolone acetonide	0.1%	ointment
	Triamcinolone acetonide	0.1%	ointment
High Potency (Group 2)	Amcinonide	0.1%	ointment
	Betamethasone dipropionate, augmented (Diprolene®)	0.05%	cream, lotion
	Betamethasone dipropionate, unaugmented (Diprosone®)	0.05%	cream, ointment
	Desoximetasone	0.25%	cream, ointment, spray
	Desoximetasone	0.05%	gel
	Diflorasone diacetate	0.05%	ointment
	Fluocinonide	0.05%	cream, gel, ointment, solution
	Halcinonide	0.1%	cream
	Mometasone furoate	0.1%	ointment
	Triamcinolone acetonide	0.5%	ointment
Super-High Potency (Group 1)	Betamethasone dipropionate, augmented (Diprolene®)	0.05%	gel, ointment
	Clobetasol propionate	0.05%	cream, foam, gel, lotion, ointment, shampoo, spray
	Diflorasone diacetate	0.05%	ointment
	Fluocinonide	0.1%	cream
	Flurandrenolide	4 mcg/cm ²	tape
	Halobetasol propionate	0.05%	cream, ointment

Appendix 3: New Comparative Clinical Trials

A total of 113 citations were manually reviewed from the initial literature search. After further review, 113 citations were excluded because of wrong study design (e.g., observational), comparator (e.g., no control or placebo-controlled), or outcome studied (e.g., non-clinical).

Appendix 4: Medline Search Strategy

Ovid MEDLINE(R) ALL <1946 to June 09, 2026>

1	exp Psoriasis/th [Therapy]	5341
2	exp Dermatitis, Atopic/th [Therapy]	2953
3	exp Eczema/th [Therapy]	1170
4	exp Vitiligo/th [Therapy]	1203
5	Anti-Inflammatory Agents/ or Glucocorticoids/	178578
6	Administration, Topical/	42456
7	alclometasone.mp.	46
8	Betamethasone/	6553
9	Clobetasol/	1618
10	Desonide/	107
11	Desoximetasone/	84
12	Fluocinolone Acetonide/	1527
13	Hydrocortisone/	81040
14	Triamcinolone/	4177
15	amcinonide.mp.	56
16	clocortolone.mp.	27
17	flurandrenolide.mp.	22
18	Fluticasone/	3181
19	Halcinonide/	49
20	halobetasol.mp.	142
21	Mometasone Furoate/	968
22	1 or 2 or 3 or 4	10285
23	5 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21	261150
24	6 and 23	7746
25	22 and 24	142
26	limit 25 to (english language and humans)	113